MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmj.38666.653600.55

Медицинская библиотека · BMJ (Clinical research ed.) · 2005

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.

Jespersen Christian M, Als-Nielsen Bodil, Damgaard Morten, Hansen Jørgen Fischer, Hansen Stig, Helø Olav H, Hildebrandt Per, Hilden Jørgen, Jensen Gorm B, Kastrup Jens, Kolmos Hans Jørn, Kjøller Erik, Lind Inga, Nielsen Henrik, Petersen Lars, Gluud Christian, CLARICOR Trial Group

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

To determine if the macrolide clarithromycin affects mortality and cardiovascular morbidity in patients with stable coronary heart disease.

DESIGN

Centrally randomised multicentre trial. All parties at all stages were blinded. Analyses were by intention to treat.

SETTING

Five Copenhagen University cardiology departments and a coordinating centre.

PARTICIPANTS

13,702 patients aged 18 to 85 years who had a discharge diagnosis of myocardial infarction or angina pectoris in 1993-9 and alive in August 1999 were invited by letter; 4373 were randomised.

INTERVENTIONS: Two weeks' treatment with clarithromycin 500 mg/day or matching placebo.

PRIMARY OUTCOME: composite of all cause mortality, myocardial infarction, or unstable angina pectoris during three years' follow-up. Secondary outcome: composite of cardiovascular mortality, myocardial infarction, or unstable angina pectoris. The outcomes were obtained from Danish registers and were blindly assessed by the event committee.

RESULTS

2172 participants were randomised to clarithromycin and 2201 to placebo. We found no significant effects of clarithromycin on the primary outcome (hazard ratio 1.15, 95% confidence interval 0.99 to 1.34) or secondary outcome (1.17, 0.98 to 1.40). Mortality was significantly higher in the clarithromycin arm (1.27, 1.03 to 1.54; P = 0.03) as a result of significantly higher cardiovascular mortality (1.45, 1.09 to 1.92; P = 0.01).

CONCLUSIONS

Short term clarithromycin in patients with stable coronary heart disease may cause significantly higher cardiovascular mortality. The long term safety of clarithromycin in patients with stable ischaemic heart disease should be examined. Trial registration ClinicalTrials.gov NCT00121550.

Для цитирования: Jespersen Christian M, Als-Nielsen Bodil, Damgaard Morten, Hansen Jørgen Fischer, Hansen Stig, Helø Olav H, Hildebrandt Per, Hilden Jørgen, Jensen Gorm B, Kastrup Jens, Kolmos Hans Jørn, Kjøller Erik, Lind Inga, Nielsen Henrik, Petersen Lars, Gluud Christian, CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.. BMJ (Clinical research ed.). 2005. DOI: 10.1136/bmj.38666.653600.55.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.